Form 4: Lineage Cell Therapeutics Director Anula Jayasuriya Granted Stock Options

Lineage Cell Therapeutics, Inc. Director Anula Jayasuriya was granted 75,000 stock options with an exercise price of $0.8977, vesting on the earlier of July 1, 2026, or the next annual shareholder meeting.

Summary

• Anula Jayasuriya, a Director of Lineage Cell Therapeutics, Inc. (LCTX), was granted 75,000 stock options.
• The stock options have an exercise price of $0.8977 per share.
• The earliest transaction date for this grant is July 1, 2025.
• The options will vest and become exercisable on the earlier of July 1, 2026, and the date of the issuer's next annual meeting of shareholders.
• Vesting is subject to Ms. Jayasuriya's continuous service with Lineage Cell Therapeutics.
• The expiration date for these stock options is July 1, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns management interests with shareholders, generally viewed as a neutral to slightly positive development.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The stock options granted to Director Anula Jayasuriya are set to vest and become exercisable on the earlier of July 1, 2026, or the date of the issuer's next annual meeting of shareholders, contingent upon her continuous service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and cell therapy industry, serving as a key component of executive and director compensation packages designed to attract and retain talent while aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if the options are exercised.

Next Steps

• The stock options will vest and become exercisable on the earlier of July 1, 2026, and the date of the issuer's next annual meeting of shareholders, subject to continuous service.

Key Dates

Keywords

Lineage Cell Therapeutics, LCTX, Anula Jayasuriya, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology, Cell Therapy